Importantly, blockade of IL‐1 signalling in patients with type 2 diabetes with recombinant human IL‐1Ra (Anakinra) has also been shown to improve glycaemic control and β‐cell function and reduced markers of systemic inflammation.13 The gene discussed is IL1B; the disease is type 2 diabetes mellitus.